{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:06:03Z","timestamp":1784178363133,"version":"3.55.0"},"reference-count":123,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Generating personalized anti-tumor immune responses remains a primary objective of precision oncology, yet conventional autologous platforms face critical biological and logistical constraints. While current research modifies allogeneic lines to evade host clearance, this perspective outlines a translational framework designed to leverage host-donor incompatibility as an active immunomodulatory asset to remodel the solid tumor microenvironment (TME). The framework proposes expanding a systemic pool of circulating, allo-specific host type 1 helper (Th1) memory cells via iterative intradermal injections of completely mismatched, activated donor Th1 cells, followed by a systemic intravenous rechallenge to provoke a controlled host-versus-graft (HvG) rejection response. Rapid intravascular clearance of donor cells is hypothesized to drive a transient, Type 1 cytokine wave that activates host effector populations via bystander pathways, promoting their extravasation into the tumor stroma to induce immunogenic cell death (ICD). This paradigm is contextualized by Phase 2B data in refractory microsatellite stable (MSS) metastatic colorectal cancer, where a dual-route allogeneic Th1 regimen demonstrated a median overall survival (OS) signal of 16.4 months despite an 89.5% conventional radiological progression rate. Ultimately, this framework provides a predictable, non-engineered conceptual mechanism to elicit a patient-specific adaptive immune response without ex vivo customization.<\/jats:p>","DOI":"10.3390\/vaccines14070619","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:06:52Z","timestamp":1784084812000},"page":"619","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Generating Patient-Specific Anti-Tumor Responses with Non-Genetically Altered \u2018Off-the-Shelf\u2019 Allogeneic Cell Therapy: Leveraging Allo-Incompatibility for In Situ Vaccination"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9342-9337","authenticated-orcid":false,"given":"Michael","family":"Har-Noy","sequence":"first","affiliation":[{"name":"Immunovative Therapies, Ltd., Jerusalem 9610203, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1007\/s00262-018-2158-4","article-title":"Personalized cancer vaccines: Adjuvants are important, too","volume":"67","author":"Gouttefangeas","year":"2018","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"oyaf431","DOI":"10.1093\/oncolo\/oyaf431","article-title":"Ready or not, here they come: A practical guide to adoptive T-cell therapies for solid tumors for medical oncologists","volume":"31","author":"Hoang","year":"2026","journal-title":"Oncologists"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"102883","DOI":"10.1016\/j.tranon.2026.102883","article-title":"Clinical translation of an immunomodulatory cell therapy that is designed to convert \u201ccold\u201d tumors to \u201chot\u201d: A phase 2B trial in 3L MSS\/pMMR metastatic colorectal cancer","volume":"71","author":"Hirschfeld","year":"2026","journal-title":"Transl. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pao, S.C., Chu, M.T., and Hung, S.I. (2022). Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14040867"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Buonaguro, L., and Tagliamonte, M. (2020). Selecting Target Antigens for Cancer Vaccine Development. Vaccines, 8.","DOI":"10.3390\/vaccines8040615"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.4110\/in.2026.26.e12","article-title":"Integrating Three Functional Subsets of T Cell Immunity into an Integrative Model for Cancer Immunotherapy","volume":"26","author":"Park","year":"2026","journal-title":"Immune Netw."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.semcancer.2007.06.006","article-title":"Mobilizing the low-avidity T cell repertoire to kill tumors","volume":"17","author":"McMahan","year":"2007","journal-title":"Semin. Cancer Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"npj Vaccines"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100052","DOI":"10.1016\/j.iotech.2021.100052","article-title":"Computational cancer neoantigen prediction: Current status and recent advances","volume":"12","author":"Fotakis","year":"2021","journal-title":"Immunooncol. Technol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/2159-8290.CD-20-1575","article-title":"Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches","volume":"11","author":"Gupta","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.21037\/jtd.2018.03.60","article-title":"The evolving understanding of immunoediting and the clinical impact of immune escape","volume":"10","author":"McCoach","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_14","first-page":"236","article-title":"Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: What we (don\u2019t) know","volume":"39","author":"Camelliti","year":"2020","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Saylor, K., Gillam, F., Lohneis, T., and Zhang, C. (2020). Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00283"},{"key":"ref_16","first-page":"38","article-title":"T-cell infiltration and its regulatory mechanisms in cancers: Insights at single-cell resolution","volume":"43","author":"Yang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: Moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Gupta, A., Das, R., Reed, K., Jeon, T., Nguyen, Q.T.C., Rudra, A., Ge, X., Trongjit, S., Vanrobaeys, Y.S., and Langer, R. (2026). Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models. Nat. Biotechnol., Epub ahead of print.","DOI":"10.1038\/s41587-026-03115-2"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e005755","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: Pooled analysis of consecutive cohorts of the C-144-01 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Liu, C., Yang, X., Paoli-Bruno, J., Sikes, D., Marin-Ruiz, A.V., Thomas, N., Shane, R., and Har-Noy, M. (2025). Allo-Priming Reverses Immunosenescence and May Restore Broad Respiratory Viral Protection and Vaccine Responsiveness to the Elderly: Results of a Phase I\/II Clinical Trial. Vaccines, 1.","DOI":"10.20944\/preprints202503.2194.v1"},{"key":"ref_21","first-page":"225","article-title":"Bringing cell therapy to tumors: Considerations for optimal CAR binder design","volume":"6","author":"Smith","year":"2023","journal-title":"Antib. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Shanshal, M., Caimi, P.F., Adjei, A.A., and Ma, W.W. (2023). T-Cell Engagers in Solid Cancers-Current Landscape and Future Directions. Cancers, 15.","DOI":"10.3390\/cancers15102824"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.4049\/jimmunol.1700236","article-title":"Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains","volume":"200","author":"Harris","year":"2018","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.trecan.2024.01.003","article-title":"Targeting solid tumor antigens with chimeric receptors: Cancer biology meets synthetic immunology","volume":"10","author":"Kembuan","year":"2024","journal-title":"Trends Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e2206912","DOI":"10.1002\/advs.202206912","article-title":"Overcoming the On-Target Toxicity in Antibody-Mediated Therapies via an Indirect Active Targeting Strategy","volume":"10","author":"Tang","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_27","first-page":"S1","article-title":"Toxicity of Chimeric Antigen Receptor T Cells and its Management","volume":"4","author":"Wudhikarn","year":"2021","journal-title":"Blood Cell Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"14378","DOI":"10.1136\/jitc-2025-014378","article-title":"HosTIL territory: Mapping the landscape of toxicity in TIL therapy","volume":"14","author":"Woodford","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"(2025). Risk of secondary T-cell malignancy after CAR T-cell therapy. Drug Ther. Bull., 63, 148.","DOI":"10.1136\/dtb.2025.000023"},{"key":"ref_31","unstructured":"US Food and Drug Administration (FDA) (2024). Safety Labeling Changes Requested for Chimeric Antigen Receptor (CAR) T-Cell Immunotherapies Regulated by the Center for Biologics Evaluation and Research (CBER) to Address the Risk of T-Cell Malignancies, US Food and Drug Administration (FDA)."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Stevens, A.J., and Lim, W.A. (2026). DROP-CARs: Engineering Reversible, Drug-Controlled CAR T Cell Activity with a Clinically Approved Small Molecule. Cancer Res.","DOI":"10.1158\/0008-5472.CAN-26-1348"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41570-025-00768-6","article-title":"Small-molecule control of CAR T cells","volume":"9","author":"Adams","year":"2025","journal-title":"Nat. Rev. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: Design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.18632\/oncotarget.15218","article-title":"A versatile system for rapid multiplex genome-edited CAR T cell generation","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Li, Y.-R., Chen, Y., and Yang, L. (2026). Stealth designs to overcome allorejection in engineered cell therapy. Trends Immunol., online ahead of print.","DOI":"10.1016\/j.it.2026.02.008"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kim, H. (2025). Overcoming Immune Barriers in Allogeneic CAR-NK Therapy: From Multiplex Gene Editing to AI-Driven Precision Design. Biomolecules, 15.","DOI":"10.3390\/biom15070935"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12943-025-02334-6","article-title":"Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy","volume":"24","author":"Lu","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/EDBK_180328","article-title":"Adoptive T-Cell Therapy for Solid Tumors","volume":"37","author":"Yeku","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educ. Book\/ASCO. Am. Soc. Clin. Oncol. Meet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"105208","DOI":"10.1016\/j.critrevonc.2026.105208","article-title":"Natural killer and CAR-NK cell therapies in urological cancers: Progress, mechanistic lessons from CAR-T, and future directions","volume":"221","author":"Zhou","year":"2026","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s43556-026-00447-y","article-title":"In vivo CAR-cell therapy: Current challenges and emerging therapeutic advances","volume":"7","author":"Yang","year":"2026","journal-title":"Mol. Biomed."},{"key":"ref_42","unstructured":"Phacilitate Insights Architecture Group (2025). Emerging Regulatory and Transduction Safety Boundaries in In Vivo Cell and Gene Processing, Phacilitate Insights Architecture Group."},{"key":"ref_43","unstructured":"American Society of Hematology (ASH) Clinical Immunotherapy Study Group (2025). Pharmacokinetic decay curves and short-lived effector windows of non-viral in vivo mRNA-LNP cell reprogramming platforms in solid tissue malignancies. Proceedings of the Blood (Annual Meeting Abstracts Supplement), American Society of Hematology (ASH) Clinical Immunotherapy Study Group."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.copbio.2020.06.008","article-title":"Mechanogenetics for cellular engineering and cancer immunotherapy","volume":"66","author":"Zhu","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Perez, C., Gruber, I., and Arber, C. (2020). Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring \u201cUniversal\u201d Donor T Cells. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.583716"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Huisman, W., Leboux, D.A.T., van der Maarel, L.E., Hageman, L., Amsen, D., Falkenburg, J.H.F., and Jedema, I. (2021). Magnitude of Off-Target Allo-HLA Reactivity by Third-Party Donor-Derived Virus-Specific T Cells Is Dictated by HLA-Restriction. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.630440"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.stem.2023.02.009","article-title":"Advancing cell-based cancer immunotherapy through stem cell engineering","volume":"30","author":"Li","year":"2023","journal-title":"Cell Stem Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e001608","DOI":"10.1136\/jitc-2020-001608","article-title":"\u2018Off-the-shelf\u2019 allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies","volume":"9","author":"Sinha","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Cornel, A.M., Mimpen, I.L., and Nierkens, S. (2020). MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy. Cancers, 12.","DOI":"10.3390\/cancers12071760"},{"key":"ref_52","first-page":"755","article-title":"Targeting gamma delta T cells for cancer immunotherapy: Bench to bedside","volume":"138","author":"Gogoi","year":"2013","journal-title":"Indian. J. Med. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"101764","DOI":"10.1016\/j.xcrm.2024.101764","article-title":"Pan-cancer gammadelta TCR analysis uncovers clonotype diversity and prognostic potential","volume":"5","author":"Yu","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12929-025-01125-x","article-title":"Biological functions and therapeutic applications of human mucosal-associated invariant T cells","volume":"32","author":"Fang","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Rotolo, A., Mason, N.J., and Exley, M.A. (2025). Innate iNKT cells: From biological insight to clinical impact. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1653183"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1038\/s41467-019-13113-5","article-title":"Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants","volume":"10","author":"Koenig","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Martinez, M., and Moon, E.K. (2019). CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00128"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Tay, C., Qian, Y., and Sakaguchi, S. (2020). Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy. Cancers, 13.","DOI":"10.3390\/cancers13010048"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.celrep.2017.06.079","article-title":"An Atlas of Human Regulatory T Helper-like Cells Reveals Features of Th2-like Tregs that Support a Tumorigenic Environment","volume":"20","author":"Halim","year":"2017","journal-title":"Cell Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/2326-6066.CIR-25-0514","article-title":"T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy","volume":"14","author":"Wittling","year":"2026","journal-title":"Cancer Immunol. Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Chikovani, T., and Magen, E. (2025). In Situ Vaccination by Tumor Ablation: Principles and Prospects for Systemic Antitumor Immunity. Vaccines, 13.","DOI":"10.3390\/vaccines13111114"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ijrobp.2020.08.023","article-title":"Radiation Therapy and the In Situ Vaccination Approach","volume":"108","author":"Golden","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2174\/0115680266384226251013054011","article-title":"Contemporary Developments in PROTACs for Cancer Management: An In-Depth Review","volume":"26","author":"Rahaman","year":"2026","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Shen, Y., Huang, W., Nie, J., and Zhang, L. (2025). Progress Update on STING Agonists as Vaccine Adjuvants. Vaccines, 13.","DOI":"10.3390\/vaccines13040371"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2217\/imt-2022-0137","article-title":"Combining in situ vaccination and immunogenic apoptosis to treat cancer","volume":"15","author":"Kalami","year":"2023","journal-title":"Immunotherapy"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ijrobp.2012.06.020","article-title":"Radiation therapy to convert the tumor into an in situ vaccine","volume":"84","author":"Formenti","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_67","first-page":"e29620","article-title":"A Review of the Abscopal Effect in the Era of Immunotherapy","volume":"14","author":"Nabrinsky","year":"2022","journal-title":"Cureus"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semradonc.2014.07.005","article-title":"Radiotherapy and immunogenic cell death","volume":"25","author":"Golden","year":"2015","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e09836","DOI":"10.1002\/advs.202509836","article-title":"In Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical Translation","volume":"12","author":"Shi","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"117194","DOI":"10.1016\/j.bcp.2025.117194","article-title":"Transforming the \u201ccold\u201d tumors to \u201chot\u201d tumors: Strategies for immune activation","volume":"241","author":"Kong","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Martin, K., Schreiner, J., and Zippelius, A. (2015). Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00501"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Murshid, A., Gong, J., and Calderwood, S.K. (2012). The role of heat shock proteins in antigen cross presentation. Front. Immunol., 3.","DOI":"10.3389\/fimmu.2012.00063"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1126\/science.7545313","article-title":"A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides","volume":"269","author":"Suto","year":"1995","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"111281","DOI":"10.1016\/j.cellsig.2024.111281","article-title":"Metabolic crosstalk: Extracellular ATP and the tumor microenvironment in cancer progression and therapy","volume":"121","author":"Shukla","year":"2024","journal-title":"Cell. Signal."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"14915","DOI":"10.1038\/s41598-017-14848-1","article-title":"Identification of pharmacological agents that induce HMGB1 release","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-025-02264-1","article-title":"Pattern recognition receptors: Function, regulation and therapeutic potential","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Ham, H., Medlyn, M., and Billadeau, D.D. (2022). Locked and Loaded: Mechanisms Regulating Natural Killer Cell Lytic Granule Biogenesis and Release. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.871106"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.4049\/jimmunol.0803954","article-title":"Cytokine secretion is distinct from secretion of cytotoxic granules in NK cells","volume":"184","author":"Reefman","year":"2010","journal-title":"J. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Gaggero, S., Witt, K., Carlsten, M., and Mitra, S. (2020). Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.621225"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.mehy.2007.10.008","article-title":"The anti-tumor effect of allogeneic bone marrow\/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?","volume":"70","author":"Slavin","year":"2008","journal-title":"Med. Hypotheses"},{"key":"ref_81","first-page":"1","article-title":"The activation of bystander CD8+ T cells and their roles in viral infection","volume":"51","author":"Kim","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.celrep.2013.02.020","article-title":"Bystander-activated memory CD8 T cells control early pathogen load in an innate-like, NKG2D-dependent manner","volume":"3","author":"Chu","year":"2013","journal-title":"Cell Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1084\/jem.175.1.305","article-title":"Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection","volume":"175","author":"Benichou","year":"1992","journal-title":"J. Exp. Med."},{"key":"ref_84","first-page":"282","article-title":"The alloresponse","volume":"1","author":"Baker","year":"1999","journal-title":"Rev. Immunogenet."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/MOT.0000000000000263","article-title":"Direct and indirect allograft recognition: Pathways dictating graft rejection mechanisms","volume":"21","author":"Lin","year":"2016","journal-title":"Curr. Opin. Organ Transplant."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.leukres.2008.08.017","article-title":"Allogeneic CD3\/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia\/lymphoma","volume":"33","author":"Zeira","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12967-020-02363-3","article-title":"Allo-priming as a universal anti-viral vaccine: Protecting elderly from current COVID-19 and any future unknown viral outbreak","volume":"18","author":"Or","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.leukres.2008.05.007","article-title":"Completely mismatched allogeneic CD3\/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity","volume":"32","author":"Zeira","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"156376","DOI":"10.1016\/j.cyto.2023.156376","article-title":"Uncovering the complex role of interferon-gamma in suppressing type 2 immunity to cancer","volume":"171","author":"Bhat","year":"2023","journal-title":"Cytokine"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.trim.2015.07.007","article-title":"Pre-transplant donor-specific Interferon-gamma-producing cells and acute rejection of the kidney allograft","volume":"33","author":"Slavcev","year":"2015","journal-title":"Transpl. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Tvedt, T.H.A., Vo, A.K., Bruserud, O., and Reikvam, H. (2021). Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences. J. Clin. Med., 10.","DOI":"10.3390\/jcm10215190"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2002-12-3949","article-title":"Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: Critical role for recipient-derived IFN-gamma","volume":"102","author":"Rubio","year":"2003","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clim.2006.03.004","article-title":"Role of indirect allo- and autoreactivity in anti-tumor responses induced by recipient leukocyte infusions (RLI) in mixed chimeras prepared with nonmyeloablative conditioning","volume":"120","author":"Rubio","year":"2006","journal-title":"Clin. Immunol."},{"key":"ref_96","first-page":"55","article-title":"Natural killer cells and interferon","volume":"5","author":"Welsh","year":"1984","journal-title":"Crit. Rev. Immunol."},{"key":"ref_97","first-page":"3399","article-title":"A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice","volume":"61","author":"Nakajima","year":"2001","journal-title":"Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"516789","DOI":"10.1155\/2012\/516789","article-title":"Integrin trafficking and tumor progression","volume":"2012","author":"Shin","year":"2012","journal-title":"Int. J. Cell Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","article-title":"Interferon-gamma: Teammate or opponent in the tumour microenvironment?","volume":"22","author":"Gocher","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Reschke, R., Enk, A.H., and Hassel, J.C. (2024). Chemokines and Cytokines in Immunotherapy of Melanoma and Other Tumors: From Biomarkers to Therapeutic Targets. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25126532"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Minnar, C.M., Lui, G., Gulley, J.L., Schlom, J., and Gameiro, S.R. (2023). Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1321318"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.currproblcancer.2015.10.003","article-title":"The immune mechanisms of abscopal effect in radiation therapy","volume":"40","author":"Grass","year":"2016","journal-title":"Curr. Probl. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","article-title":"The abscopal effect of local radiotherapy: Using immunotherapy to make a rare event clinically relevant","volume":"41","author":"Reynders","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41419-024-06992-0","article-title":"The different paradigms of NK cell death in patients with severe trauma","volume":"15","author":"Chang","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Solari, J.I.G., Filippi-Chiela, E., Pilar, E.S., Nunes, V., Gonzalez, E.A., Figueiro, F., Andrade, C.F., and Klamt, F. (2020). Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06964-5"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Salvi","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.4049\/jimmunol.1101812","article-title":"Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-gamma-dependent mechanism","volume":"187","author":"LaCasse","year":"2011","journal-title":"J. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2217\/imt.09.35","article-title":"Why current peptide-based cancer vaccines fail: Lessons from the three Es","volume":"1","author":"Claesson","year":"2009","journal-title":"Immunotherapy"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"17837","DOI":"10.1038\/s41598-024-68789-7","article-title":"Modulation of MHC expression by interferon-gamma and its influence on PBMC-mediated cytotoxicity in canine mast cell tumour cells","volume":"14","author":"Bhanpattanakul","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1186\/s12967-024-05572-2","article-title":"Nilotinib boosts the efficacy of anti-PDL1 therapy in colorectal cancer by restoring the expression of MHC-I","volume":"22","author":"Dong","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Yosri, M., Dokhan, M., Aboagye, E., Al Moussawy, M., and Abdelsamed, H.A. (2024). Mechanisms governing bystander activation of T cells. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1465889"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.cell.2017.05.005","article-title":"Interferon-gamma Drives T(reg) Fragility to Promote Anti-tumor Immunity","volume":"169","author":"Chikina","year":"2017","journal-title":"Cell"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1182\/blood-2010-06-288621","article-title":"Allogeneic effector\/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia","volume":"117","author":"Janikashvili","year":"2011","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/eji.201444497","article-title":"IFN-gamma regulates survival and function of tumor-induced CD11b+ Gr-1high myeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1","volume":"44","author":"Haile","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ijc.24401","article-title":"Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages","volume":"125","author":"Duluc","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"109332","DOI":"10.1016\/j.intimp.2022.109332","article-title":"The role of CCL2, CCL7, ICAM-1, and VCAM-1 in interaction of endothelial cells and natural killer cells","volume":"113","author":"Kim","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41231-024-00174-y","article-title":"Objective response after immune checkpoint inhibitors in a chemotherapy-refractory pMMR\/MSS metastatic rectal cancer patient primed with experimental AlloStim\u00ae immunotherapy","volume":"9","author":"Hirschfeld","year":"2024","journal-title":"Transl. Med. Commun."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.2018.36.5_suppl.115","article-title":"Effect of therapeutic vaccine on CTLA4 and tumor debulking response in recurrent and metastatic HNSCC","volume":"36","author":"Chindavijak","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"S1272","DOI":"10.1016\/j.annonc.2020.10.098","article-title":"78P Novel allogeneic cell immunotherapy for advanced cancers","volume":"31","author":"Kananathan","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e13013","DOI":"10.1200\/jco.2012.30.15_suppl.e13013","article-title":"Response of HER2+ breast cancer patients to allogeneic cell immunotherapy","volume":"30","author":"Lausoontornsiri","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12943-024-02140-6","article-title":"Artificial intelligence alphafold model for molecular biology and drug discovery: A machine-learning-driven informatics investigation","volume":"23","author":"Guo","year":"2024","journal-title":"Mol. Cancer"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/619\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:44:05Z","timestamp":1784177045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":123,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["vaccines14070619"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14070619","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}